About Event

5th Targeted Radiopharmaceuticals Summit Europe

Be Part of the Only Event Dedicated to Mastering the Complexity of Targeted Radiopharmaceuticals

Across 3 days of unparalleled content, showcasing companies including Novartis, Bayer, Telix Pharmaceuticals, Bristol-Myers Squibb, Fusion Pharmaceuticals and more, this conference provided a deep dive into the novel target, supply chain issue, dosimetry problems, combination therapies.

Why Our Audience Attended:

Understand
the investor
landscape
to maximise
investments and
opportunities to
help drive TRP
development
with Novartis
and Bristol-Myers Squibb

Answer
fundamental
regulatory
questions within
the EU to meet
regulatory
expectations
on isotopes
and targeting
molecules with
Regulanova
Sarl

Hone dosimetry
to increase the
adaptability of
therapy and
overcome the
one size fits all
assumption to
increase patient
specificity and
produce a TRP
with high efficacy
with INSERM

Take a deep
dive into
novel targets
such as FAP
and HER2 to
address unmet
needs through
new treatment
modalities with
Precirix

Overcome
supply chain
challenges with
novel isotopes
to hasten TRP
manufacturing
and understand
clinical utility to
increase speed
to clinic with
ImaginAb